Invitae deploys Apple Watch for cardiovascular genetics study

By staff writers

November 15, 2019 -- Invitae has developed a research platform that links test results for genetic conditions with biometric data amassed on the Apple Watch.

The first application of the platform -- dubbed Invitae Discover -- will be cardiovascular disease, the company said in an announcement ahead of the of the American Heart Association (AHA) annual meeting taking place November 16-18 in Philadelphia.

Apple Watch health features include the ability to track abnormal heart rhythms, which could help with the early diagnosis of atrial fibrillation. Invitae is conducting a study called Afib CAUSE that will look at the role of genetics in atrial fibrillation and other cardiovascular conditions, incorporating the biometric data of Apple Watch users. Participants can enroll through an Invitae Discover app available from the Apple App Store. As part of the research project, Invitae said it will study known variants associated with atrial fibrillation, as well as variants of unknown significance.

Invitae will also point out the limitations of highly targeted direct-to-consumer testing for familial hypercholesterolemia in an AHA session on November 17 about genomic medicine. The company warned of false positives on targeted consumer tests in a study presented at the American Society of Human Genetics annual meeting in October, a claim that competitor 23andMe said was biased and unfounded.

Quest reports supportive data for new HDL cholesterol function test
Quest Diagnostics reported data supporting its new test for high-density lipoprotein (HDL) cholesterol function at the American Heart Association annual...
Big data can improve familial hypercholesterolemia screening
A machine-learning algorithm may be useful for scanning electronic health records to spot people with undiagnosed familial hypercholesterolemia based...
Invitae warns of false negatives on consumer tests
Direct-to-consumer genetic tests that provide limited screening put people at risk for false-negative results, according to a study by Invitae presented...
Cardiologists back more screening, tight LDL and glucose control
Researchers made a strong call for genetic screening for heterozygous familial hypercholesterolemia at the European Society of Cardiology and World Congress...
AACC: Labs grapple with 'double-edged sword' of direct-to-consumer testing
ANAHEIM, CA - Direct-to-consumer testing has great potential to get patients engaged about their health and to broaden access to medical information,...

Copyright © 2019

Last Updated np 11/15/2019 1:04:14 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.